GentiBio

Seattle, United States

GentiBio is a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune allergic diseases.

Aug 2021

Series A

Top Investors

RA Capital ManagementOrbiMedAvidity PartnersNovartis Venture FundSeattle Children’s

19,000+ verified contacts

Emails, phones & LinkedIn profiles

Who are GentiBio's investors?

GentiBio's investors include RA Capital Management, OrbiMed, Avidity Partners, Novartis Venture Fund, Seattle Children’s.

Where is GentiBio headquartered?

GentiBio is headquartered in Seattle, United States.

What does GentiBio do?

GentiBio is a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune allergic diseases.

What stage is GentiBio at?

GentiBio is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated August 11, 2021.

MLA

"GentiBio — Funding & Investors." VCBacked, August 11, 2021, https://www.vcbacked.co/company/gentibio. Accessed July 1, 2026.

APA

VCBacked. (2021). GentiBio — Funding & Investors. Retrieved July 1, 2026, from https://www.vcbacked.co/company/gentibio

Wikipedia (cite web)

{{cite web |title=GentiBio — Funding & Investors |url=https://www.vcbacked.co/company/gentibio |website=VCBacked |access-date=July 1, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated August 11, 2021.